(redirected from Biologic License Application)
Also found in: Medical.
Category filter:
BLABiologic License Application (US FDA)
BLABachelor of Landscape Architecture
BLABasic Linear Algebra
BLABlocking Acknowledgement
BLABasolateral Amygdala
BLABlack Liberation Army
BLABalochistan Liberation Army
BLABoard of Landscape Architects (various locations)
BLABridged Line Appearance (telephony)
BLABoundary Line Adjustment (city planning)
BLABoston Latin Academy
BLABachelor of Liberal Arts
BLABoating Law Administrator
BLABasic Living Allowance (various organizations)
BLABlocking Acknowledgement (ITU-T)
BLABetter Left Alone
BLABarcelona, Venezuela - Gral Jose Antonio Anzoategui (Airport Code)
BLABlocks Lactic Acid
BLABath Leadership Academy (UK)
BLABlack Lung Association
BLABritish Liberation Army (World War II unit)
BLABlack Lawyer Association
BLABiologics License Agreement (US FDA)
BLABuffalo Lacrosse Academy (New York)
BLABaseline Agreement
BLABattle for Lion's Arch (gaming)
BLABest Linear Approximation
BLABase Level Assessment
BLABureau of Legislative Affairs
BLABruno Legrand Architecture (France)
BLABank Loan Agreement
BLABody Loading Assembly (weapons)
BLABidirectional Line Amplifier
BLABlood Loss Anemia
BLABracket & Linkage Assembly
BLABill Low and Associates (Abbotsford, BC, Canada)
BLABasilian Lay Associate (Toronto, ON, Canada)
BLABasic Loan Agreement
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The analyst said he anticipates FDA Biologic License Application approval during the second half of 2020, with the progression-free survival, or PFS, win and OS trending positive in the SOPHIA study, and noted that the SOPHIA data showed that patients treated with margetuximab plus chemotherapy experienced a 24% risk reduction in PFS compared to patients in the trastuzumab plus chemotherapy.
ALK-Abello, a Denmark-based pharmaceutical company, announced on Friday that the FDA Allergenic Products Advisory Committee of the US Food and Drug Administration will meet on January 28, 2014 to discuss the biologic license application for the investigational ragweed sublingual allergy immunotherapy tablet.
Following the conclusion of this trial, MiMedx intends to file a Biologic License Application with the U.S.